Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01114672 · ClinicalTrials.gov registry record · Phase 4

A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients

A Phase 4 study of Pruritis, sponsored by Winthrop University Hospital.

Completed
Registry status
Phase 4
Development phase
50
Enrollment target
2
Study locations

NCT01114672 is a Phase 4 study of Pruritis that has completed, run by Winthrop University Hospital. The registered enrollment target is 50 participants. The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01114672, a Phase 4 study of Pruritis, has completed, sponsored by Winthrop University Hospital.

COMPLETED
Registry status
Phase 4
Development phase
50 participants
Enrollment target
2
Study locations

Study Summary

Pruritis (itching) is common in many people with chronic renal failure on hemodialysis. There may be many different reasons for the pruritis. Efforts to treat the problem have not been very effective. Vitamin D levels have been found to be low in many hemodialysis patients. Since vitamin D plays an important role in the skin and is effective in treatment of certain skin conditions that involve pruritis, it may have a role in treatment of pruritis in hemodialysis patients. The objective of the investigators study is to determine the effect of supplementation with oral vitamin D2 (ergocalciferol) on pruritis in hemodialysis patients.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG 50,000 Units Ergocalciferol

Study Locations (2)

New York

  • Winthop Univ Hospital Outpatient Dialysis at Bethpage - Bethpage
  • Winthrop Univ Hospital Outpatient Dialysis - Mineola

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2010-07
Est. Completion 2012-02
Phase Phase 4

Sponsor

Winthrop University Hospital

32 total trials

What the Registry Record Tells You About NCT01114672

The ClinicalTrials.gov registry entry for NCT01114672 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Winthrop University Hospital, which has 32 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pruritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01114672 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01114672 about?

NCT01114672 is a clinical study titled "A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients". Pruritis (itching) is common in many people with chronic renal failure on hemodialysis. There may be many different reasons for the pruritis. Efforts to treat the problem have not been very effective. Vitamin D levels have been found to be low in many hemodialysis patients. Since vitamin D plays an...

What is the current status of trial NCT01114672?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2010-07. Estimated completion is 2012-02.

What conditions does trial NCT01114672 study?

This clinical trial studies the following conditions: Pruritis.

What interventions are being tested in trial NCT01114672?

The interventions under investigation include: Placebo (DRUG), 50,000 Units Ergocalciferol (DRUG).

Who is sponsoring clinical trial NCT01114672?

This trial is sponsored by Winthrop University Hospital, which has 32 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01114672 being conducted?

This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pruritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.